A Phase 1, Open-label, 2-part Study of the Absorption, Metabolism, Excretion, and Bioavailability of [14C]-LY4065967 in Healthy Male Participants
Latest Information Update: 02 Jul 2025
At a glance
- Drugs LY 4065967 (Primary) ; LY 4065967 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
Most Recent Events
- 02 Jul 2025 New trial record